Studies biomarkers that may predict response to chemotherapy and immunotherapy in early breast cancer
Analyzes samples from adults with early triple negative breast cancer receiving treatment.
Plain-language title generated from the registry record
Registry title: Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
Key facts
- Where
- Barcelona, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with early triple negative breast cancer (stage 2 to 3) who are going to get chemotherapy before surgery, with or without an immune checkpoint inhibitor.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Triple negative breast cancer: HER2, estrogen receptor and progesterone receptor all negative. Stage 2 to 3 (AJCC 8th edition).
- Earlier treatment
- The patient must be a candidate for chemotherapy before surgery (NACT), with or without an immune checkpoint inhibitor, as judged by the investigator.
- Biomarker or test result
- HER2, estrogen receptor and progesterone receptor must all be negative.
Main reasons for not taking part
- Cancer that has spread to other organs (stage 4) seen on imaging
Read by machine on 12 November 2026.
Where in Spain
- Vall d'Hebron Institute of OncologyBarcelona, SpainContact: Mafalda Oliveira, MD PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Vall d'Hebron Institute of Oncology
- Trial code
- NCT05916755
- Record updated
- 23 June 2023
- Original description
Patients with stage II-III Triple negative breast cancer (TNBC) candidates to receive neoadjuvant chemotherapy (NACT) +/- immune checkpoint inhibitor (ICI) will be included. Several samples from different tissues will be analyzed through different omics to establish predictive biomarkers of response to the treatment. Multiple algorithms will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs in order to develop a clinical tool to assist clinicians in the process of treatment decision-making in TNBC.Read full original descriptionShow less
Identification of Predictive Biomarkers of Response to Chemotherapy and Immune Checkpoint Inhibitors in Early Triple Negative Breast Cancer: an Integrative Multiomics Platform
Patients with stage II-III Triple negative breast cancer (TNBC) candidates to receive neoadjuvant chemotherapy (NACT) +/- immune checkpoint inhibitor (ICI) will be included. Several samples from different tissues will be analyzed through different omics to establish predictive biomarkers of response to the treatment. Multiple algorithms will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs in order to develop a clinical tool to assist clinicians in the process of treatment decision-making in TNBC.
Inclusion: Histologically documented TNBC (negative human epidermal growth factor receptor 2 [HER2], estrogen receptor [ER], and progesterone receptor [PgR] status); Stage 2 - 3 defined by the American Joint Committee of Cancer (AJCC) staging criteria 8th edition for breast cancer as assessed by the investigator based on radiological and/or clinical assessment; Patient is a candidate to receive NACT with or without ICI as assessed by the investigator; Patient is ≥ 18 years old at the time of consent to participate in this trial.
Exclusion: Metastatic disease on imaging (stage 4).